PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31467965-0	2019	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.	ricolinostat	64-76	histone deacetylase 6	Homo sapiens	48-53
31160511-0	2019	Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.	ricolinostat	88-95	histone deacetylase 6	Homo sapiens	58-63
30664664-6	2019	Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux.	ricolinostat	50-58	histone deacetylase 6	Mus musculus	34-39
30664664-6	2019	Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux.	ricolinostat	50-58	cyclin-dependent kinase 4	Mus musculus	94-98
30664664-6	2019	Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux.	ricolinostat	50-58	cyclin D1	Mus musculus	100-109
30664664-6	2019	Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux.	ricolinostat	50-58	breast cancer 1, early onset	Mus musculus	115-120
30664664-8	2019	Furthermore, ATM loss severely impairs phosphorylation of 53BP1 following co-treatment with CB-5083 and ACY-1215 in response to gamma irradiation.	ricolinostat	104-112	ataxia telangiectasia mutated	Mus musculus	13-16
30664664-8	2019	Furthermore, ATM loss severely impairs phosphorylation of 53BP1 following co-treatment with CB-5083 and ACY-1215 in response to gamma irradiation.	ricolinostat	104-112	transformation related protein 53 binding protein 1	Mus musculus	58-63
31244662-1	2019	Background: ACY-1215 is a well-known selective histone deacetylase 6 (HDAC6) inhibitor, and it has been considered as a potential therapeutic drug in inflammatory diseases, including acute liver failure (ALF).	ricolinostat	12-20	histone deacetylase 6	Mus musculus	47-68
31244662-1	2019	Background: ACY-1215 is a well-known selective histone deacetylase 6 (HDAC6) inhibitor, and it has been considered as a potential therapeutic drug in inflammatory diseases, including acute liver failure (ALF).	ricolinostat	12-20	histone deacetylase 6	Mus musculus	70-75
30551507-0	2019	ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-kappaB signaling pathways.	ricolinostat	0-8	signal transducer and activator of transcription 3	Homo sapiens	121-126
30728070-11	2019	The frequency, FOXP3 expression, and suppressive function of T regulatory cells (Tregs) were decreased after exposure to ACY-1215 or ACY-241.	ricolinostat	121-129	forkhead box P3	Homo sapiens	15-20
30728070-13	2019	After ACY-1215 treatment, increased chromatin accessibility was observed in regions associated with T-cell effector function and memory phenotypes, while condensed chromatin was found in regions encoding the mTOR downstream molecules AKT, SGK1 and S6K.	ricolinostat	6-14	serum/glucocorticoid regulated kinase 1	Homo sapiens	239-243
30728070-13	2019	After ACY-1215 treatment, increased chromatin accessibility was observed in regions associated with T-cell effector function and memory phenotypes, while condensed chromatin was found in regions encoding the mTOR downstream molecules AKT, SGK1 and S6K.	ricolinostat	6-14	ribosomal protein S6 kinase B1	Homo sapiens	248-251
30551507-5	2019	Furthermore, ACY-1215 exerts potent chondroprotection through the amelioration of cartilage degradation by inhibiting the expression of matrix-degrading proteases, including MMP-1 and MMP-13 in chondrocytes.	ricolinostat	13-21	matrix metallopeptidase 1	Homo sapiens	174-179
30728070-9	2019	The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).	ricolinostat	31-39	histone deacetylase 6	Homo sapiens	4-9
30728070-9	2019	The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).	ricolinostat	31-39	interleukin 4	Homo sapiens	122-126
30728070-9	2019	The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).	ricolinostat	31-39	interleukin 5	Homo sapiens	128-132
30728070-9	2019	The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).	ricolinostat	31-39	interleukin 6	Homo sapiens	134-138
30728070-9	2019	The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).	ricolinostat	31-39	interleukin 10	Homo sapiens	140-145
30728070-9	2019	The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).	ricolinostat	31-39	interleukin 13	Homo sapiens	150-155
30788349-0	2019	Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells.	ricolinostat	42-49	histone deacetylase 6	Homo sapiens	0-21
30551507-2	2019	ACY-1215, a selective HDAC6 inhibitor, has been reported to have anti-inflammatory effects.	ricolinostat	0-8	histone deacetylase 6	Homo sapiens	22-27
30551507-5	2019	Furthermore, ACY-1215 exerts potent chondroprotection through the amelioration of cartilage degradation by inhibiting the expression of matrix-degrading proteases, including MMP-1 and MMP-13 in chondrocytes.	ricolinostat	13-21	matrix metallopeptidase 13	Homo sapiens	184-190
30551507-3	2019	Here, we investigated the anti-inflammatory and chondroprotective effects of ACY-1215 in IL-1beta-stimulated human primary chondrocytes and C28/I2 cells.	ricolinostat	77-85	interleukin 1 beta	Homo sapiens	89-97
30551507-6	2019	These effects may be related to ACY-1215 induced down-regulation of NF-kappaB and STAT3 pathways in OA chondrocytes.	ricolinostat	32-40	signal transducer and activator of transcription 3	Homo sapiens	82-87
30788349-1	2019	Background: ACY1215 is a selective histone deacetylase 6 (HDAC6) inhibitor, and can suppress tumor growth for many human cancers.	ricolinostat	12-19	histone deacetylase 6	Homo sapiens	35-56
30788349-1	2019	Background: ACY1215 is a selective histone deacetylase 6 (HDAC6) inhibitor, and can suppress tumor growth for many human cancers.	ricolinostat	12-19	histone deacetylase 6	Homo sapiens	58-63
30551507-4	2019	The results suggested that ACY-1215 can markedly suppress the expression of inflammatory factors, including IL-1beta and IL-6 in human primary chondrocytes and C28/I2 cells.	ricolinostat	27-35	interleukin 1 beta	Homo sapiens	108-116
30551507-4	2019	The results suggested that ACY-1215 can markedly suppress the expression of inflammatory factors, including IL-1beta and IL-6 in human primary chondrocytes and C28/I2 cells.	ricolinostat	27-35	interleukin 6	Homo sapiens	121-125
29749542-0	2018	The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.	ricolinostat	20-28	histone deacetylase 6	Homo sapiens	4-9
30788349-8	2019	Conclusions: Selective HDAC6 inhibitor, ACY1215, could inhibit the cell proliferation, migration and invasion, and induce apoptosis of HCT116 colon cancer cells.	ricolinostat	40-47	histone deacetylase 6	Homo sapiens	23-28
30028995-0	2018	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.	ricolinostat	109-121	ATP binding cassette subfamily B member 1	Homo sapiens	40-45
30028995-0	2018	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.	ricolinostat	109-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	50-55
30028995-0	2018	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.	ricolinostat	109-121	histone deacetylase 6	Homo sapiens	77-98
30028995-0	2018	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.	ricolinostat	123-131	ATP binding cassette subfamily B member 1	Homo sapiens	40-45
30028995-0	2018	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.	ricolinostat	123-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	50-55
30028995-0	2018	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.	ricolinostat	123-131	histone deacetylase 6	Homo sapiens	77-98
30028995-3	2018	In this study, we investigated the potential impact of multidrug resistance-linked ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 on the efficacy of ricolinostat, which may present a major hurdle to its development as an anticancer drug in the future.	ricolinostat	158-170	ATP binding cassette subfamily B member 1	Homo sapiens	123-128
30028995-3	2018	In this study, we investigated the potential impact of multidrug resistance-linked ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 on the efficacy of ricolinostat, which may present a major hurdle to its development as an anticancer drug in the future.	ricolinostat	158-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	133-138
29749542-1	2018	ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies.	ricolinostat	0-8	histone deacetylase 6	Homo sapiens	51-72
29749542-1	2018	ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies.	ricolinostat	24-36	histone deacetylase 6	Homo sapiens	51-72
27589363-5	2017	Clustering analysis allowed identifying the most populated conformers present during the MD simulation, which were used as starting models to perform docking calculations with five DD2-HDAC6 inhibitors: Cay10603 (CAY), Rocilinostat (RCT), Tubastatin A (TBA), Tubacin (TBC), and Nexturastat (NXT), and then were also submitted to 100-ns-long MD simulations.	ricolinostat	233-236	histone deacetylase 6	Homo sapiens	181-190
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	0-12	microRNA 30d	Mus musculus	114-121
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	0-12	thymoma viral proto-oncogene 1	Mus musculus	127-130
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	0-12	mechanistic target of rapamycin kinase	Mus musculus	131-135
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	0-12	mitogen-activated protein kinase 1	Mus musculus	140-143
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	14-22	microRNA 30d	Mus musculus	114-121
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	14-22	thymoma viral proto-oncogene 1	Mus musculus	127-130
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	14-22	mechanistic target of rapamycin kinase	Mus musculus	131-135
30050135-0	2018	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.	ricolinostat	14-22	mitogen-activated protein kinase 1	Mus musculus	140-143
30050135-1	2018	Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers.	ricolinostat	0-12	histone deacetylase 6	Mus musculus	52-57
30050135-1	2018	Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers.	ricolinostat	14-22	histone deacetylase 6	Mus musculus	52-57
30050135-5	2018	We further demonstrated that ACY-1215 treatment reduced the expression of PI3K, P-AKT, P-mTOR, and P-ERK1/2 and increased that of Ac-H3K9 and Ac-H4K8.	ricolinostat	29-37	thymoma viral proto-oncogene 1	Mus musculus	82-85
30050135-5	2018	We further demonstrated that ACY-1215 treatment reduced the expression of PI3K, P-AKT, P-mTOR, and P-ERK1/2 and increased that of Ac-H3K9 and Ac-H4K8.	ricolinostat	29-37	mechanistic target of rapamycin kinase	Mus musculus	89-93
30050135-7	2018	Anti-miR-30d partially rescued the G2/M phase arrest and apoptosis caused by ACY-1215 treatment.	ricolinostat	77-85	microRNA 30d	Mus musculus	5-12
30050135-10	2018	In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC.	ricolinostat	37-45	microRNA 30d	Mus musculus	106-113
30050135-10	2018	In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC.	ricolinostat	37-45	thymoma viral proto-oncogene 1	Mus musculus	119-122
30050135-10	2018	In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC.	ricolinostat	37-45	mechanistic target of rapamycin kinase	Mus musculus	123-127
30050135-10	2018	In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC.	ricolinostat	37-45	mitogen-activated protein kinase 1	Mus musculus	132-135
29760044-5	2018	Combined treatment of human and mouse SCLC cell line-derived xenograft tumors with the HDAC6 inhibitor ricolinostat (ACY-1215) and JQ1 demonstrated significant inhibition of tumor growth; this effect was abolished upon depletion of NK cells, suggesting that these innate immune lymphoid cells play a role in SCLC tumor treatment response.	ricolinostat	117-125	histone deacetylase 6	Mus musculus	87-92
30043566-0	2018	ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.	ricolinostat	0-8	histone deacetylase 6	Mus musculus	12-33
30043566-3	2018	ACY 1215 (ricolinostat), a selective HDAC6 inhibitor, is currently being clinically trialed in multiple cancers but not in melanoma.	ricolinostat	0-8	histone deacetylase 6	Mus musculus	37-42
30043566-3	2018	ACY 1215 (ricolinostat), a selective HDAC6 inhibitor, is currently being clinically trialed in multiple cancers but not in melanoma.	ricolinostat	10-22	histone deacetylase 6	Mus musculus	37-42
29483217-8	2018	Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression.	ricolinostat	76-84	DNA damage inducible transcript 3	Homo sapiens	125-129
29112935-0	2018	Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-kappaB pathway.	ricolinostat	32-40	histone deacetylase 6	Mus musculus	0-21
29112935-0	2018	Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-kappaB pathway.	ricolinostat	32-40	toll-like receptor 4	Mus musculus	109-113
29112935-2	2018	ACY-1215 is a selective histone deacetylase 6 inhibitor, and it has been recognized as a potential anticancer and anti-inflammation drug.	ricolinostat	0-8	histone deacetylase 6	Mus musculus	24-45
29112935-14	2018	Pretreatment of ACY-1215 significantly decreased the protein expression of TLR4 and the activation of MAPK and NF-kappaB signalling pathways.	ricolinostat	16-24	toll-like receptor 4	Mus musculus	75-79
29112935-15	2018	ACY-1215 has potential therapeutic value in mice with ALF by directly inhibiting inflammatory response via regulation of the TLR4-MAPK/NF-kB pathway.	ricolinostat	0-8	toll-like receptor 4	Mus musculus	125-129
28452069-5	2017	This effect was specific for tubacin, as inhibition of HDAC6 deacetylase activity by another selective HDAC6 inhibitor, ACY-1215 or the pan-HDAC inhibitor trichostatin A (TSA), and knockdown of HDAC6 did not enhance the release of CD133+ EVs.	ricolinostat	120-128	histone deacetylase 6	Homo sapiens	55-60
28452069-5	2017	This effect was specific for tubacin, as inhibition of HDAC6 deacetylase activity by another selective HDAC6 inhibitor, ACY-1215 or the pan-HDAC inhibitor trichostatin A (TSA), and knockdown of HDAC6 did not enhance the release of CD133+ EVs.	ricolinostat	120-128	histone deacetylase 9	Homo sapiens	55-59
28747357-0	2017	An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease.	ricolinostat	48-56	histone deacetylase 6	Mus musculus	16-37
28747357-4	2017	Treatment with ACY-1215 slowed cyst growth in a mouse model of ADPKD that forms massive cysts within 3 wk after knockout of polycystin 1 function.	ricolinostat	15-23	polycystin 1, transient receptor potential channel interacting	Mus musculus	124-136
28747357-7	2017	We found that ACY-1215 lowered cAMP levels and protein expression of adenylyl cyclase 6.	ricolinostat	14-22	adenylate cyclase 6	Mus musculus	69-87
28819043-6	2017	We also showed that late administration of ACY-1215 and tubastatin A, two potent and selective inhibitors of HDAC6, rescued the tau-induced MT defects after the abnormalities had already become apparent.	ricolinostat	43-51	histone deacetylase 6	Homo sapiens	109-114
28819043-6	2017	We also showed that late administration of ACY-1215 and tubastatin A, two potent and selective inhibitors of HDAC6, rescued the tau-induced MT defects after the abnormalities had already become apparent.	ricolinostat	43-51	microtubule associated protein tau	Homo sapiens	128-131
29108192-5	2017	ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05).	ricolinostat	0-7	glutamic pyruvic transaminase, soluble	Mus musculus	103-106
29108192-5	2017	ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05).	ricolinostat	0-7	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	108-111
29108192-5	2017	ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05).	ricolinostat	0-7	tumor necrosis factor	Mus musculus	128-137
29108192-5	2017	ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05).	ricolinostat	0-7	interferon gamma	Mus musculus	143-152
29108192-6	2017	ACY1215 also significantly reduced the expression of NF-kappaB-p65 (t = -5.871, P = 0.004) and the mRNA expression of TNF-alpha (t = -11.913, P < 0.01) in brain tissue and brain water content (t = -2.355, P < 0.01).	ricolinostat	0-7	tumor necrosis factor	Mus musculus	118-127
28053023-0	2017	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.	ricolinostat	0-12	histone deacetylase 9	Homo sapiens	34-53
28270494-11	2017	Combination of SJB and HDACi ACY-1215, bortezomib, lenalidomide, or pomalidomide triggers synergistic cytotoxicity.Conclusions: Our preclinical studies provide the framework for clinical evaluation of USP1 inhibitors, alone or in combination, as a potential novel multiple myeloma therapy.	ricolinostat	29-37	ubiquitin specific peptidase 1	Homo sapiens	201-205
28408401-4	2017	By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells.	ricolinostat	98-110	histone deacetylase 6	Homo sapiens	82-87
28267067-7	2017	These findings were confirmed using the established HDAC6 inhibitor ACY-1215 (Ricolinostat), which is currently in clinical trials for cancer treatment.	ricolinostat	68-76	histone deacetylase 6	Mus musculus	52-57
27993968-3	2017	ACY-1215 (ricolinostat) is a first-in-class selective HDAC6 inhibitor.	ricolinostat	0-8	histone deacetylase 6	Homo sapiens	54-59
27993968-3	2017	ACY-1215 (ricolinostat) is a first-in-class selective HDAC6 inhibitor.	ricolinostat	10-22	histone deacetylase 6	Homo sapiens	54-59
27993968-10	2017	In vivo confirmation of antitumor synergy was demonstrated with a xenograft of DLBCL.Conclusions: The development of this ACY-1215-resistant cell line has provided valuable insights into the mechanistic role of HDAC6 in lymphoma and offered a novel method to identify rational synergistic drug combinations.	ricolinostat	122-130	histone deacetylase 6	Homo sapiens	211-216
28315173-0	2017	Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.	ricolinostat	0-12	histone deacetylase 6	Homo sapiens	26-31
28267067-7	2017	These findings were confirmed using the established HDAC6 inhibitor ACY-1215 (Ricolinostat), which is currently in clinical trials for cancer treatment.	ricolinostat	78-90	histone deacetylase 6	Mus musculus	52-57
27884726-6	2017	Ricolinostat and ACY-241, which selectively inhibit HDAC6 and the aggresome pathway, are currently being studied in combination with dexamethasone and bortezomib or an immunomodulatory drug for the treatment of relapsed and refractory MM.	ricolinostat	0-12	histone deacetylase 6	Homo sapiens	52-57
27957719-8	2017	Three different inhibitors (ACY-738, ACY-775, and ACY-1215) were tested and demonstrated to be both potent and selective HDAC6 inhibitors.	ricolinostat	50-58	histone deacetylase 6	Mus musculus	121-126
28076695-8	2017	Early data from clinical trials investigating the HDAC6 inhibitor ricolinostat are also discussed.	ricolinostat	66-78	histone deacetylase 6	Homo sapiens	50-55
28035401-0	2017	ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.	ricolinostat	0-8	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	55-59
28035401-0	2017	ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.	ricolinostat	0-8	mitogen-activated protein kinase 1	Homo sapiens	127-130
28035401-7	2017	ACY-1215, a selective HDAC6 inhibitor, inhibits the proliferation and induces the apoptosis of A375 cells.	ricolinostat	0-8	histone deacetylase 6	Homo sapiens	22-27
28035401-8	2017	Moreover, ACY-1215 sensitizes A375 cells to vemurafenib induced cell proliferation inhibition and apoptosis induction, which occur partly through induction of endoplasmic reticulum (ER) stress and inactivation of extracellular signal-regulated kinase (ERK).	ricolinostat	10-18	mitogen-activated protein kinase 1	Homo sapiens	213-250
28035401-8	2017	Moreover, ACY-1215 sensitizes A375 cells to vemurafenib induced cell proliferation inhibition and apoptosis induction, which occur partly through induction of endoplasmic reticulum (ER) stress and inactivation of extracellular signal-regulated kinase (ERK).	ricolinostat	10-18	mitogen-activated protein kinase 1	Homo sapiens	252-255
26643555-9	2015	We thus demonstrated that Ricolinostat (ACY1215), a leading HDAC6 inhibitor, efficiently controls IBC cell proliferation both in vitro and in vivo.	ricolinostat	26-38	histone deacetylase 6	Homo sapiens	60-65
27646843-2	2016	Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically.	ricolinostat	0-12	histone deacetylase 6	Homo sapiens	52-57
27646843-2	2016	Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically.	ricolinostat	0-12	histone deacetylase 9	Homo sapiens	52-56
27646843-2	2016	Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically.	ricolinostat	14-22	histone deacetylase 6	Homo sapiens	52-57
27646843-2	2016	Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically.	ricolinostat	14-22	histone deacetylase 9	Homo sapiens	52-56
27646843-19	2016	INTERPRETATION: The findings from this study provide preliminary evidence that ricolinostat is a safe and well tolerated selective HDAC6 inhibitor, which might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or refractory multiple myeloma.	ricolinostat	79-91	histone deacetylase 6	Homo sapiens	131-136
26643555-9	2015	We thus demonstrated that Ricolinostat (ACY1215), a leading HDAC6 inhibitor, efficiently controls IBC cell proliferation both in vitro and in vivo.	ricolinostat	40-47	histone deacetylase 6	Homo sapiens	60-65
26116270-0	2015	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.	ricolinostat	82-90	histone deacetylase 6	Mus musculus	66-71
26150340-3	2015	GBM cell growth was significantly inhibited by ACY-1215, a specific HDAC6 inhibitor.	ricolinostat	47-55	histone deacetylase 6	Homo sapiens	68-73
26116270-4	2015	We investigated the mechanism and therapeutic impact of the selective HDAC6 inhibitor ACY-1215 alone and in combination with bortezomib in preclinical models of lymphoma.	ricolinostat	86-94	histone deacetylase 6	Mus musculus	70-75
25458911-6	2015	METHODS: We assessed the clinical and biological effects of ACY-1215, an HDAC6-specific inhibitor, by using murine CD8 T cell-related skin disease models, including contact hypersensitivity (CHS) and experimental graft-versus-host disease (GVHD)-like disease.	ricolinostat	60-68	histone deacetylase 6	Mus musculus	73-78
25978432-7	2015	Importantly ACY1215, an HDAC6 inhibitor with minimal effects on class-I HDACs, together with Len induces synergistic MM cytotoxicity without alteration of CRBN expression.	ricolinostat	12-19	histone deacetylase 6	Homo sapiens	24-29
25239935-0	2014	In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.	ricolinostat	62-74	histone deacetylase 6	Homo sapiens	46-51
25239935-0	2014	In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.	ricolinostat	76-83	histone deacetylase 6	Homo sapiens	46-51
25239935-7	2014	Combined exposure to carfilzomib and ricolinostat also markedly downregulated the cargo-loading protein HR23B.	ricolinostat	37-49	RAD23 homolog B, nucleotide excision repair protein	Homo sapiens	104-109
25239935-8	2014	Moreover, HR23B knockdown significantly increased carfilzomib- and ricolinostat-mediated lethality, suggesting a role for this event in cell death.	ricolinostat	67-79	RAD23 homolog B, nucleotide excision repair protein	Homo sapiens	10-15
22262760-0	2012	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.	ricolinostat	102-110	histone deacetylase 6	Homo sapiens	85-90
24471924-4	2014	In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat.	ricolinostat	333-345	chorionic somatomammotropin hormone 1	Homo sapiens	191-194
24434010-6	2014	Furthermore, pharmacological inhibition of HDAC6 by Tubastatin-A, Tubacin, and ACY-1215 decreased proliferation of cystic cholangiocytes in a dose- and time-dependent manner, and inhibited cyst growth in three-dimensional cultures.	ricolinostat	79-87	histone deacetylase 6	Rattus norvegicus	43-48
24434010-7	2014	Importantly, ACY-1215 administered to PCK rats diminished liver cyst development and fibrosis.	ricolinostat	13-21	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	38-41
22262760-3	2012	In the present study, we investigated the preclinical activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.	ricolinostat	66-74	histone deacetylase 6	Homo sapiens	79-84
22262760-4	2012	Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.	ricolinostat	13-21	caspase 3	Homo sapiens	172-181
22262760-4	2012	Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.	ricolinostat	13-21	caspase 8	Homo sapiens	183-192
22262760-4	2012	Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.	ricolinostat	13-21	caspase 9	Homo sapiens	198-207
22262760-7	2012	Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 hours after treatment coincident with an increase in acetylated alpha-tubulin, a marker of HDAC6 inhibition, by immunohistochemistry and Western blot analysis.	ricolinostat	50-58	histone deacetylase 6	Homo sapiens	155-160
34958116-3	2022	In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21.	ricolinostat	90-98	histone deacetylase 6	Mus musculus	67-88
34958116-3	2022	In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21.	ricolinostat	90-98	transformation related protein 53, pseudogene	Mus musculus	132-135
34958116-3	2022	In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21.	ricolinostat	90-98	transformation related protein 53, pseudogene	Mus musculus	172-175
34958116-3	2022	In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21.	ricolinostat	90-98	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	226-229
34958116-4	2022	These results suggested that ACY-1215 may lead to enhanced transcriptional activity of p53.	ricolinostat	29-37	transformation related protein 53, pseudogene	Mus musculus	87-90
34958116-6	2022	Furthermore, ACY-1215 displayed a synergistic effect with specific inhibitors of ATM, an activator of Akt, in inducing cancer cell apoptosis and inhibiting their motility.	ricolinostat	13-21	ataxia telangiectasia mutated	Mus musculus	81-84
34958116-6	2022	Furthermore, ACY-1215 displayed a synergistic effect with specific inhibitors of ATM, an activator of Akt, in inducing cancer cell apoptosis and inhibiting their motility.	ricolinostat	13-21	thymoma viral proto-oncogene 1	Mus musculus	102-105
34958116-7	2022	More importantly, it was observed that combination of ACY-1215 and ATM inhibitors exhibited markedly more potent antitumor activity than the individual compound in xenograft mouse models of breast cancer with mutant p53.	ricolinostat	54-62	transformation related protein 53, pseudogene	Mus musculus	216-219
34958116-8	2022	Collectively, our results demonstrated that ACY-1215 is a novel chemotherapeutic agent that could restore mutant p53 function in cancer cells with strong antitumor activity, either alone or in combination with inhibitors of the ATM protein kinase.	ricolinostat	44-52	transformation related protein 53, pseudogene	Mus musculus	113-116
34958116-8	2022	Collectively, our results demonstrated that ACY-1215 is a novel chemotherapeutic agent that could restore mutant p53 function in cancer cells with strong antitumor activity, either alone or in combination with inhibitors of the ATM protein kinase.	ricolinostat	44-52	ataxia telangiectasia mutated	Mus musculus	228-231
34524571-5	2021	Inhibition of HDAC6 via its specific inhibitor ACY1215 restores chemosensitivity of OS-resistant cells.	ricolinostat	47-54	histone deacetylase 6	Homo sapiens	14-19
34524571-7	2021	Inhibition of ERRalpha further strengthens ACY1215-increased chemosensitivity of OS-resistant cells.	ricolinostat	43-50	estrogen related receptor alpha	Homo sapiens	14-22
34329468-4	2021	Screening of 1813 small-molecule compounds resulted in the identification of Ricolinostat (an HDAC6 inhibitor) that can enhance the efficiency of BE3 in human cells (2.45- to 9.21-fold improvement).	ricolinostat	77-89	histone deacetylase 6	Homo sapiens	94-99
34345305-3	2021	The aim of the present study was to investigate the effect of combination treatment with the proteasome inhibitor bortezomib (BTZ), and ricolinostat (RCS), a specific inhibitor of histone deacetylase 6 (HDAC6), on CAL27 and Detroit562 head and neck cancer cells.	ricolinostat	136-148	histone deacetylase 6	Homo sapiens	180-201
34345305-3	2021	The aim of the present study was to investigate the effect of combination treatment with the proteasome inhibitor bortezomib (BTZ), and ricolinostat (RCS), a specific inhibitor of histone deacetylase 6 (HDAC6), on CAL27 and Detroit562 head and neck cancer cells.	ricolinostat	136-148	histone deacetylase 6	Homo sapiens	203-208
34329468-7	2021	Meanwhile, combined application of BE3 and Ricolinostat led to >3-fold higher efficiency of correcting a pathogenic mutation in ABCA4 gene related to Stargardt disease in human cells.	ricolinostat	43-55	ATP binding cassette subfamily A member 4	Homo sapiens	128-133
34180140-9	2021	Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment.	ricolinostat	110-117	steroid sulfatase	Mus musculus	63-66
34180140-0	2021	HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway.	ricolinostat	16-23	histone deacetylase 6	Mus musculus	0-5
34180140-0	2021	HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway.	ricolinostat	16-23	NLR family, pyrin domain containing 3	Mus musculus	51-56
34180140-0	2021	HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway.	ricolinostat	16-23	ataxia telangiectasia mutated	Mus musculus	111-114
34180140-3	2021	Our findings suggested that ACY1215 treatment ameliorates the pathological hepatic damage of ALF and decreases the serum levels of ALT and AST.	ricolinostat	28-35	glutamic pyruvic transaminase, soluble	Mus musculus	131-134
34180140-3	2021	Our findings suggested that ACY1215 treatment ameliorates the pathological hepatic damage of ALF and decreases the serum levels of ALT and AST.	ricolinostat	28-35	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	139-142
34180140-4	2021	Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF.	ricolinostat	13-20	ataxia telangiectasia mutated	Mus musculus	57-60
34180140-4	2021	Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF.	ricolinostat	13-20	H2A.X variant histone	Mus musculus	62-72
34180140-4	2021	Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF.	ricolinostat	13-20	checkpoint kinase 2	Mus musculus	74-78
34180140-4	2021	Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF.	ricolinostat	13-20	transformation related protein 53, pseudogene	Mus musculus	80-83
34180140-4	2021	Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF.	ricolinostat	13-20	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	85-88
34180140-4	2021	Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF.	ricolinostat	13-20	vinculin	Mus musculus	102-110
34180140-5	2021	Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF.	ricolinostat	10-17	NLR family, pyrin domain containing 3	Mus musculus	41-46
34180140-5	2021	Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF.	ricolinostat	10-17	steroid sulfatase	Mus musculus	48-51
34180140-5	2021	Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF.	ricolinostat	10-17	caspase 1	Mus musculus	53-62
34180140-5	2021	Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF.	ricolinostat	10-17	interleukin 1 alpha	Mus musculus	64-72
34180140-5	2021	Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF.	ricolinostat	10-17	interleukin 18	Mus musculus	77-82
34180140-6	2021	The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	120-127	ataxia telangiectasia mutated	Mus musculus	4-7
34180140-6	2021	The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	120-127	ataxia telangiectasia mutated	Mus musculus	54-57
34180140-6	2021	The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	120-127	H2A.X variant histone	Mus musculus	59-69
34180140-6	2021	The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	120-127	checkpoint kinase 2	Mus musculus	71-75
34180140-6	2021	The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	120-127	transformation related protein 53, pseudogene	Mus musculus	77-80
34180140-6	2021	The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	120-127	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	82-85
34180140-6	2021	The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	120-127	vinculin	Mus musculus	99-107
34180140-7	2021	The F-actin inhibitor cytochalasin B decreased the level of F-actin and vinculin in ALF with ACY1215 pretreatment.	ricolinostat	93-100	vinculin	Mus musculus	72-80
34180140-9	2021	Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment.	ricolinostat	110-117	NLR family, pyrin domain containing 3	Mus musculus	56-61
34180140-9	2021	Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment.	ricolinostat	110-117	caspase 1	Mus musculus	68-77
34180140-9	2021	Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment.	ricolinostat	110-117	interleukin 1 alpha	Mus musculus	79-87
34180140-9	2021	Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment.	ricolinostat	110-117	interleukin 18	Mus musculus	92-97
34180140-10	2021	These results indicated that ACY1215 exhibited hepatoprotective properties, which was associated with the inhibition of NLRP3 inflammasome, and this effect of ACY1215 was connected with upregulation of the ATM/F-actin mediated signalling pathways.	ricolinostat	29-36	NLR family, pyrin domain containing 3	Mus musculus	120-125
34180140-10	2021	These results indicated that ACY1215 exhibited hepatoprotective properties, which was associated with the inhibition of NLRP3 inflammasome, and this effect of ACY1215 was connected with upregulation of the ATM/F-actin mediated signalling pathways.	ricolinostat	29-36	ataxia telangiectasia mutated	Mus musculus	206-209
34180140-10	2021	These results indicated that ACY1215 exhibited hepatoprotective properties, which was associated with the inhibition of NLRP3 inflammasome, and this effect of ACY1215 was connected with upregulation of the ATM/F-actin mediated signalling pathways.	ricolinostat	159-166	ataxia telangiectasia mutated	Mus musculus	206-209
35167193-6	2022	Next, we demonstrated that inhibition of HDAC6 function, using the HDAC6-specific inhibitor ACY1215 or by transfection with HDAC6 short hairpin RNA (shRNA), can reverse the migratory and invasive phenotype of ARID1A-knockdown cells.	ricolinostat	92-99	histone deacetylase 6	Mus musculus	41-46
35614130-3	2022	Here, through small-molecule screening focusing on epigenetic modifiers during the in vitro Th1 cell differentiation process, we identified that the selective histone deacetylase 6 (HDAC6) inhibitors ricolinostat and nexturastat A (Nex A) promoted Th1 cell differentiation.	ricolinostat	200-212	histone deacetylase 6	Mus musculus	182-187
35167193-6	2022	Next, we demonstrated that inhibition of HDAC6 function, using the HDAC6-specific inhibitor ACY1215 or by transfection with HDAC6 short hairpin RNA (shRNA), can reverse the migratory and invasive phenotype of ARID1A-knockdown cells.	ricolinostat	92-99	histone deacetylase 6	Mus musculus	67-72
35167193-6	2022	Next, we demonstrated that inhibition of HDAC6 function, using the HDAC6-specific inhibitor ACY1215 or by transfection with HDAC6 short hairpin RNA (shRNA), can reverse the migratory and invasive phenotype of ARID1A-knockdown cells.	ricolinostat	92-99	AT rich interactive domain 1A (SWI-like)	Mus musculus	209-215
35348191-0	2022	Ricolinostat enhances adavosertib-induced mitotic catastrophe in TP53-mutated head and neck squamous cell carcinoma cells.	ricolinostat	0-12	tumor protein p53	Homo sapiens	65-69
35231828-2	2022	In the present study, the effects of ACY-1215, a specific inhibitor of HDAC6, on the acetylation of alpha-tubulin, histone epigenetic modification, spindle formation and embryonic development of early bovine SCNT embryos were studied.	ricolinostat	37-45	histone deacetylase 6	Bos taurus	71-76
33458921-0	2021	First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.	ricolinostat	42-50	histone deacetylase 6	Homo sapiens	25-30
35404520-4	2022	In particular, compound 21, obtained by constantly step-by-step simplification and evolution based on Ricolinostat, a specific HDAC6 inhibitor in Phase II, unexpectedly showed high selectivity (29 fold) and moderate potency (73 nM).	ricolinostat	102-114	histone deacetylase 6	Homo sapiens	127-132
34998817-0	2022	HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation.	ricolinostat	16-24	histone deacetylase 6	Rattus norvegicus	0-5
34998817-5	2022	The present study was dedicated to exploring the effects of ACY-1215 (a specific HDAC6 inhibitor) on neuroinflammation and behavioral abnormalities associated with NP.	ricolinostat	60-68	histone deacetylase 6	Rattus norvegicus	81-86
34998817-8	2022	Moreover, ACY-1215 administration suppressed SNL-induced neuroinflammatory responses (including microgliosis, the elevation of pro-inflammatory factors IL-1beta and TNF-alpha) in ligation of the ipsilateral spinal dorsal horn (iSDH), hippocampus (HPC) and prefrontal cortex (PFC).	ricolinostat	10-18	interleukin 1 alpha	Rattus norvegicus	152-160
34998817-8	2022	Moreover, ACY-1215 administration suppressed SNL-induced neuroinflammatory responses (including microgliosis, the elevation of pro-inflammatory factors IL-1beta and TNF-alpha) in ligation of the ipsilateral spinal dorsal horn (iSDH), hippocampus (HPC) and prefrontal cortex (PFC).	ricolinostat	10-18	tumor necrosis factor	Rattus norvegicus	165-174
34998817-9	2022	Mechanistically, MyD88-dependent pro-inflammatory pathways (MyD88/NF-kappaB and MyD88/ERK) were activated in the iSDH following SNL and were inhibited by ACY-1215.	ricolinostat	154-162	Eph receptor B1	Rattus norvegicus	86-89
34969757-3	2022	MATERIALS AND METHODS: The anti-tumor effects of ACY-1215, an HDAC6 specific inhibitor, in CCA cell lines were analyzed by cell viability assay, western blotting, flow cytometry, co-immunoprecipitation, and biotinylation assays.	ricolinostat	49-57	histone deacetylase 6	Homo sapiens	62-67
34969757-5	2022	RESULTS: ACY-1215 increased the acetyl-form of GRP78 by approximately 50% compared to control, which impaired the translocation of GRP78 to the plasma membrane by 50% through alteration of cellular proliferative signaling via PI3K/AKT.	ricolinostat	9-17	heat shock protein family A (Hsp70) member 5	Homo sapiens	47-52
34969757-5	2022	RESULTS: ACY-1215 increased the acetyl-form of GRP78 by approximately 50% compared to control, which impaired the translocation of GRP78 to the plasma membrane by 50% through alteration of cellular proliferative signaling via PI3K/AKT.	ricolinostat	9-17	heat shock protein family A (Hsp70) member 5	Homo sapiens	131-136
34969757-5	2022	RESULTS: ACY-1215 increased the acetyl-form of GRP78 by approximately 50% compared to control, which impaired the translocation of GRP78 to the plasma membrane by 50% through alteration of cellular proliferative signaling via PI3K/AKT.	ricolinostat	9-17	AKT serine/threonine kinase 1	Homo sapiens	231-234
33883923-4	2021	The ALF mice model was intervened with HDAC6 inhibitor ACY-1215.	ricolinostat	55-63	histone deacetylase 6	Mus musculus	39-44
33883923-14	2021	Conclusion: ACY-1215 could inhibit the activation of M1 macrophages by improving the glycolytic pathway through regulating DNMT1 and DDX3X/NLRP3 signals to alleviate ALF.	ricolinostat	12-20	DNA methyltransferase (cytosine-5) 1	Mus musculus	123-128
33883923-14	2021	Conclusion: ACY-1215 could inhibit the activation of M1 macrophages by improving the glycolytic pathway through regulating DNMT1 and DDX3X/NLRP3 signals to alleviate ALF.	ricolinostat	12-20	DEAD box helicase 3, X-linked	Mus musculus	133-138
33883923-14	2021	Conclusion: ACY-1215 could inhibit the activation of M1 macrophages by improving the glycolytic pathway through regulating DNMT1 and DDX3X/NLRP3 signals to alleviate ALF.	ricolinostat	12-20	NLR family, pyrin domain containing 3	Mus musculus	139-144
33915983-4	2021	We found that HDAC6 inhibitors ACY-1215 (1215) and ACY-738 (738) inhibited the proliferation of multiple patient-derived and mouse glioma cells.	ricolinostat	31-39	histone deacetylase 6	Homo sapiens	14-19
35123563-5	2022	RESULTS: The small molecule Ricolinostat remarkably promoted the expression of PF4-promoter reporter in the megakaryocytic cell line.	ricolinostat	28-40	platelet factor 4	Homo sapiens	79-82
35123563-8	2022	Mechanistically, we found that Ricolinostat enhanced MkP fate mainly by inhibiting the secretion of IL-8 and decreasing the expression of the IL-8 receptor CXCR2.	ricolinostat	31-43	C-X-C motif chemokine ligand 8	Homo sapiens	100-104
35123563-9	2022	CONCLUSION: The addition of Ricolinostat to the culture medium promoted MkP differentiation from HSPCs and enhanced the proliferation of MkPs mainly by suppressing the IL-8/CXCR2 pathway.	ricolinostat	28-40	C-X-C motif chemokine ligand 8	Homo sapiens	168-172
35123563-9	2022	CONCLUSION: The addition of Ricolinostat to the culture medium promoted MkP differentiation from HSPCs and enhanced the proliferation of MkPs mainly by suppressing the IL-8/CXCR2 pathway.	ricolinostat	28-40	C-X-C motif chemokine receptor 2	Homo sapiens	173-178
35159049-7	2022	Additionally, ACY-1215 treatment resulted in a significant reduction in OMM2.5 p-ERK expression levels.	ricolinostat	14-22	mitogen-activated protein kinase 1	Homo sapiens	81-84
35159049-8	2022	Through proteome profiling, the attenuation of the microphthalmia-associated transcription factor (MITF) signaling pathway was linked to the observed anti-cancer effects of ACY-1215.	ricolinostat	173-181	melanocyte inducing transcription factor	Homo sapiens	51-97
35159049-8	2022	Through proteome profiling, the attenuation of the microphthalmia-associated transcription factor (MITF) signaling pathway was linked to the observed anti-cancer effects of ACY-1215.	ricolinostat	173-181	melanocyte inducing transcription factor	Homo sapiens	99-103
33835029-5	2021	High-throughput compound screening with this model identified ACY-1215 as a potent latency reversing agent, which could be verified in other cell models and in primary CD4+ T cells from ART-suppressed individuals ex vivo.	ricolinostat	62-70	CD4 molecule	Homo sapiens	168-171
33458921-5	2021	BACKGROUND: ACY-1215, ricolinostat, is an oral, first-in-class isoform-selective HDAC6 inhibitor.	ricolinostat	12-20	histone deacetylase 6	Homo sapiens	81-86
33458921-5	2021	BACKGROUND: ACY-1215, ricolinostat, is an oral, first-in-class isoform-selective HDAC6 inhibitor.	ricolinostat	22-34	histone deacetylase 6	Homo sapiens	81-86
32350373-4	2021	We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies.	ricolinostat	84-96	CD38 molecule	Homo sapiens	112-116
33654196-7	2021	Significantly, we found that tektin4 loss sensitized TNBC cells, xenograft models, and patient-derived organoid models to the HDAC6-selective inhibitor ACY1215.	ricolinostat	152-159	tektin 4	Homo sapiens	29-36
33654196-7	2021	Significantly, we found that tektin4 loss sensitized TNBC cells, xenograft models, and patient-derived organoid models to the HDAC6-selective inhibitor ACY1215.	ricolinostat	152-159	histone deacetylase 6	Homo sapiens	126-131
33428788-0	2021	HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.	ricolinostat	17-24	histone deacetylase 6	Homo sapiens	0-5
33428788-2	2021	ACY1215 is a highly effective selective inhibitor of HDAC6, which can inhibit many kinds of tumors.	ricolinostat	0-7	histone deacetylase 6	Homo sapiens	53-58
33428788-8	2021	The HDAC6 inhibitor ACY1215 suppressed the proliferation of GBC-SD and SDC-996 cells and promoted the apoptosis of gallbladder cancer cells.	ricolinostat	20-27	histone deacetylase 6	Homo sapiens	4-9
33428788-9	2021	The HDAC6 inhibitor ACY1215 increases the chemotherapy effect of gemcitabine and oxaliplatin.	ricolinostat	20-27	histone deacetylase 6	Homo sapiens	4-9
33428788-10	2021	ACY1215 could suppress cell proliferation and induce apoptosis of GBC-SD and SGC-996, and increased the chemotherapy effect of gemcitabine and oxaliplatin, which provides a rationale for the combination of HDAC6 selective inhibitors with other anticancer agents in treating gallbladder cancer.	ricolinostat	0-7	histone deacetylase 6	Homo sapiens	206-211
32350373-4	2021	We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies.	ricolinostat	84-96	CD38 molecule	Homo sapiens	167-171
32350373-5	2021	Using quantitative reverse transcription polymerase chain reaction and flow cytometry, we observed that ricolinostat significantly increases CD38 RNA levels and CD38 surface expression on MM cells.	ricolinostat	104-116	CD38 molecule	Homo sapiens	141-145
32350373-5	2021	Using quantitative reverse transcription polymerase chain reaction and flow cytometry, we observed that ricolinostat significantly increases CD38 RNA levels and CD38 surface expression on MM cells.	ricolinostat	104-116	CD38 molecule	Homo sapiens	161-165
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	97-105	histone deacetylase 6	Homo sapiens	40-45
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	97-105	histone deacetylase 6	Homo sapiens	118-123
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	97-105	tubulin alpha 1b	Homo sapiens	141-154
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	97-105	tubulin alpha 1b	Homo sapiens	208-221
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	97-105	histone deacetylase 6	Homo sapiens	118-123
32435850-6	2020	Inhibition of HDAC6 with ricolinostat reduced suppressive activity of M-MDSC, but did not affect PMN-MDSC or delayed tumor growth.	ricolinostat	25-37	histone deacetylase 6	Mus musculus	14-19
33103445-3	2020	In this study, we examined the effect of ricolinostat (ACY-1215), a selective inhibitor of HDAC6, on the development of renal fibrosis in a murine model induced by unilateral ureteral obstruction (UUO).	ricolinostat	41-53	histone deacetylase 6	Mus musculus	91-96
33103445-5	2020	Administration of ACY-1215 reduced these fibrotic changes and inhibited UUO-induced expression of transforming growth factor ss1 (TGFss1) and phosphorylation of Smad3, while increasing expression of Smad7.	ricolinostat	18-26	SMAD family member 3	Mus musculus	161-166
33103445-5	2020	Administration of ACY-1215 reduced these fibrotic changes and inhibited UUO-induced expression of transforming growth factor ss1 (TGFss1) and phosphorylation of Smad3, while increasing expression of Smad7.	ricolinostat	18-26	SMAD family member 7	Mus musculus	199-204
33103445-6	2020	ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney.	ricolinostat	0-8	epidermal growth factor receptor	Mus musculus	54-86
33103445-6	2020	ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney.	ricolinostat	0-8	epidermal growth factor receptor	Mus musculus	88-92
33103445-6	2020	ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney.	ricolinostat	0-8	thymoma viral proto-oncogene 1	Mus musculus	172-175
33103445-6	2020	ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney.	ricolinostat	0-8	signal transducer and activator of transcription 3	Mus musculus	177-227
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	83-95	histone deacetylase 6	Homo sapiens	40-45
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	83-95	histone deacetylase 6	Homo sapiens	118-123
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	83-95	tubulin alpha 1b	Homo sapiens	141-154
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	83-95	tubulin alpha 1b	Homo sapiens	208-221
33322608-8	2020	Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function.	ricolinostat	83-95	histone deacetylase 6	Homo sapiens	118-123
32572875-0	2020	Histone deacetylase 6 inhibitor ACY1215 ameliorates mitochondrial dynamic and function injury in hepatocytes by activating AMPK signaling pathway in acute liver failure mice.	ricolinostat	32-39	histone deacetylase 6	Mus musculus	0-21
32572875-2	2020	The histone deacetylase 6 inhibitor Rocilinostat (ACY1215) has a hepatoprotective effect.	ricolinostat	36-48	histone deacetylase 6	Mus musculus	4-25
32572875-2	2020	The histone deacetylase 6 inhibitor Rocilinostat (ACY1215) has a hepatoprotective effect.	ricolinostat	50-57	histone deacetylase 6	Mus musculus	4-25
32572875-12	2020	ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models.	ricolinostat	0-7	collapsin response mediator protein 1	Mus musculus	69-73
32572875-12	2020	ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models.	ricolinostat	0-7	fission, mitochondrial 1	Mus musculus	78-82
32572875-12	2020	ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models.	ricolinostat	0-7	mitofusin 1	Mus musculus	137-141
32572875-12	2020	ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models.	ricolinostat	0-7	mitofusin 2	Mus musculus	143-147
32572875-12	2020	ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models.	ricolinostat	0-7	OPA1, mitochondrial dynamin like GTPase	Mus musculus	152-156
32705192-0	2020	ACY-1215, a HDAC6 inhibitor, decreases the dexamethasone-induced suppression of osteogenesis in MC3T3-E1 cells.	ricolinostat	0-8	histone deacetylase 6	Mus musculus	12-17
32615502-10	2020	Altogether, in this study we identified a novel and potent HDAC6-selective inhibitor (~4x more selective than current clinical standards - citarinostat, ricolinostat), which achieves cellular target engagement, efficacy in hematological cancer cells with a promising safety profile and in vitro PK.	ricolinostat	153-165	histone deacetylase 6	Homo sapiens	59-64
32705192-12	2020	ACY-1215 promoted the GR expression in MC3T3-E1 cells from 1-5 mM while GR receptor expression was increased with 10 mM ACY-1215 treatment.	ricolinostat	0-8	nuclear receptor subfamily 3, group C, member 1	Mus musculus	22-24
32178737-10	2020	ACY-1215- and MPT0E028-treated rats had a trend in decreased serum TGF-beta levels, but not statistically significant.	ricolinostat	0-8	transforming growth factor alpha	Rattus norvegicus	67-75
32178737-13	2020	TGF-beta and CRP should be useful biomarkers to monitor the use of ACY1215 in cardiac IR injury.	ricolinostat	67-74	C-reactive protein	Rattus norvegicus	13-16
32754596-3	2020	Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models.	ricolinostat	207-219	histone deacetylase 6	Homo sapiens	182-187
32754596-3	2020	Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models.	ricolinostat	207-219	mitogen-activated protein kinase kinase 7	Homo sapiens	238-241
32754596-3	2020	Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models.	ricolinostat	221-228	histone deacetylase 6	Homo sapiens	182-187
32754596-3	2020	Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models.	ricolinostat	221-228	mitogen-activated protein kinase kinase 7	Homo sapiens	238-241
32178737-11	2020	ACY1215-treated rats also had higher serum CRP levels compared to control rats (641.6 mug/mL vs. 961.37 +- 64.94 mug/mL, p < 0.05).	ricolinostat	0-7	C-reactive protein	Rattus norvegicus	43-46
32178737-12	2020	CONCLUSIONS: Our research indicated that HDAC6 inhibition by ACY1215 might reduce infarct size in rats with cardiac IR injury possibly through modulating HIF-1alpha expression.	ricolinostat	61-68	histone deacetylase 6	Rattus norvegicus	41-46
32178737-12	2020	CONCLUSIONS: Our research indicated that HDAC6 inhibition by ACY1215 might reduce infarct size in rats with cardiac IR injury possibly through modulating HIF-1alpha expression.	ricolinostat	61-68	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	154-164
32178737-13	2020	TGF-beta and CRP should be useful biomarkers to monitor the use of ACY1215 in cardiac IR injury.	ricolinostat	67-74	transforming growth factor alpha	Rattus norvegicus	0-8
31571096-5	2019	In the present study, we examined the effect of HDAC6 inhibitor ACY-1215 (Ricolinostat) on cisplatin-induced brain damage and cognitive deficits in mice.	ricolinostat	64-72	histone deacetylase 6	Mus musculus	48-53
31634464-12	2019	Moreover, the expression of LC3-II and beclin1 proteins were greatly reduced and the expression of p62 protein was ascended after intervention with 3-MA in ACY1215 group.	ricolinostat	156-163	beclin 1, autophagy related	Mus musculus	39-46
31634464-12	2019	Moreover, the expression of LC3-II and beclin1 proteins were greatly reduced and the expression of p62 protein was ascended after intervention with 3-MA in ACY1215 group.	ricolinostat	156-163	nucleoporin 62	Mus musculus	99-102
31634464-13	2019	SIGNIFICANCE: Histone deacetylase 6 inhibitor ACY1215 could protect acute liver failure mice and L02 cell by inhibiting apoptosis pathway through enhancing autophagy way.	ricolinostat	46-53	histone deacetylase 6	Mus musculus	14-35
31311810-5	2019	Reduced tumor burden and improved survival was observed in ARID1Aflox/flox/PIK3CAH1047R OCCC mouse treated with the HDAC6 inhibitor ACY1215 and anti-PD-L1 immune-checkpoint blockade as a result of activation and increased presence of interferon-gamma positive CD8 T cells.	ricolinostat	132-139	histone deacetylase 6	Mus musculus	116-121
31311810-5	2019	Reduced tumor burden and improved survival was observed in ARID1Aflox/flox/PIK3CAH1047R OCCC mouse treated with the HDAC6 inhibitor ACY1215 and anti-PD-L1 immune-checkpoint blockade as a result of activation and increased presence of interferon-gamma positive CD8 T cells.	ricolinostat	132-139	interferon gamma	Mus musculus	234-250
30558483-5	2019	In addition, its structural and energetic behavior was explored with each one of the catalytic domains in the molecular recognition of six selective HDAC6 inhibitors, HPOB, CAY10603, Nexturastat, Rocilinostat, Tubacin and Tubastatin A for DD2, and with the so-called 9-peptide which is DD1-HDAC6 selective substrate.	ricolinostat	196-208	histone deacetylase 6	Homo sapiens	149-154
30558483-6	2019	The use of the whole system (DD1-DMB-DD2) showed a tendency toward the ligand affinity of DD2, CAY10603> Tubacin > Rocilinostat > Nexturastat > HPOB > Tubastatin > 9-peptide, which is in line with experimental reports.	ricolinostat	115-127	aldo-keto reductase family 1 member C1	Homo sapiens	29-32
30558483-6	2019	The use of the whole system (DD1-DMB-DD2) showed a tendency toward the ligand affinity of DD2, CAY10603> Tubacin > Rocilinostat > Nexturastat > HPOB > Tubastatin > 9-peptide, which is in line with experimental reports.	ricolinostat	115-127	aldo-keto reductase family 1 member C2	Homo sapiens	37-40
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	43-55	histone deacetylase 6	Mus musculus	23-28
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	43-55	mitogen-activated protein kinase 8	Mus musculus	134-157
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	43-55	mitogen-activated protein kinase 8	Mus musculus	159-162
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	43-55	jun proto-oncogene	Mus musculus	134-139
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	57-65	histone deacetylase 6	Mus musculus	23-28
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	57-65	mitogen-activated protein kinase 8	Mus musculus	134-157
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	57-65	mitogen-activated protein kinase 8	Mus musculus	159-162
31390677-2	2020	Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.	ricolinostat	57-65	jun proto-oncogene	Mus musculus	134-139
31634464-0	2019	Histone deacetylase 6 inhibitor ACY1215 offers a protective effect through the autophagy pathway in acute liver failure.	ricolinostat	32-39	histone deacetylase 6	Mus musculus	0-21
31634464-1	2019	AIM: The purpose of the present study was to elucidate the protective effect of histone deacetylase 6 inhibitor ACY1215 on autophagy pathway in acute liver failure (ALF).	ricolinostat	112-119	histone deacetylase 6	Mus musculus	80-101
31634464-11	2019	ACY1215 could induce autophagy in ALF mice and cell model group accompanied with an increase in expression of LC3-II and beclin-1 proteins and down-regulation of p62 protein.	ricolinostat	0-7	beclin 1, autophagy related	Mus musculus	121-129
31634464-11	2019	ACY1215 could induce autophagy in ALF mice and cell model group accompanied with an increase in expression of LC3-II and beclin-1 proteins and down-regulation of p62 protein.	ricolinostat	0-7	nucleoporin 62	Mus musculus	162-165
31356453-3	2019	We show that pharmacological inhibition of HDAC6 using ACY-1215 or global deletion of HDAC6 is sufficient to prevent cisplatin-induced mechanical allodynia, loss of intraepidermal nerve fibers (IENFs), and mitochondrial bioenergetic deficits in DRG neurons and peripheral nerves in male and female mice.	ricolinostat	55-63	histone deacetylase 6	Mus musculus	43-48
31571096-5	2019	In the present study, we examined the effect of HDAC6 inhibitor ACY-1215 (Ricolinostat) on cisplatin-induced brain damage and cognitive deficits in mice.	ricolinostat	74-86	histone deacetylase 6	Mus musculus	48-53
31571096-7	2019	Mechanistically, HDAC6 inhibitor ACY-1215 enhanced alpha-tubulin acetylation in the hippocampus of cisplatin-treated mice.	ricolinostat	33-41	histone deacetylase 6	Mus musculus	17-22
31515470-7	2019	We also demonstrate that the selective HDAC6 inhibitors tubacin and ACY-1215, which prevented gp120-mediated deacetylation of tubulin, inhibited the ability of gp120 to promote neurite shortening and cell death.	ricolinostat	68-76	histone deacetylase 6	Homo sapiens	39-44
31515470-7	2019	We also demonstrate that the selective HDAC6 inhibitors tubacin and ACY-1215, which prevented gp120-mediated deacetylation of tubulin, inhibited the ability of gp120 to promote neurite shortening and cell death.	ricolinostat	68-76	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	94-99
31515470-7	2019	We also demonstrate that the selective HDAC6 inhibitors tubacin and ACY-1215, which prevented gp120-mediated deacetylation of tubulin, inhibited the ability of gp120 to promote neurite shortening and cell death.	ricolinostat	68-76	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	160-165
31500290-8	2019	Pharmacological inhibition of HDACs 1 and 2 with Romidepsin and HDAC6 with ACY-1215 also potently synergized with gemcitabine in a panel of PDAC cell lines, and this drug combination potentiated the antitumor effects of gemcitabine against PDAC xenografts in vivo.	ricolinostat	75-83	histone deacetylase 1	Homo sapiens	30-43
31500290-8	2019	Pharmacological inhibition of HDACs 1 and 2 with Romidepsin and HDAC6 with ACY-1215 also potently synergized with gemcitabine in a panel of PDAC cell lines, and this drug combination potentiated the antitumor effects of gemcitabine against PDAC xenografts in vivo.	ricolinostat	75-83	histone deacetylase 6	Homo sapiens	64-69
31548177-0	2019	Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts.	ricolinostat	0-12	vascular endothelial growth factor A	Homo sapiens	33-37
31548177-0	2019	Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts.	ricolinostat	0-12	AKT serine/threonine kinase 1	Homo sapiens	58-61
31548177-0	2019	Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts.	ricolinostat	14-22	vascular endothelial growth factor A	Homo sapiens	33-37
31548177-0	2019	Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts.	ricolinostat	14-22	AKT serine/threonine kinase 1	Homo sapiens	58-61
31548177-2	2019	As a selective HDAC6 inhibitor, Ricolinostat (ACY-1215) has demonstrated chondroprotective effects in OA.	ricolinostat	32-44	histone deacetylase 6	Homo sapiens	15-20
31548177-2	2019	As a selective HDAC6 inhibitor, Ricolinostat (ACY-1215) has demonstrated chondroprotective effects in OA.	ricolinostat	46-54	histone deacetylase 6	Homo sapiens	15-20
31548177-5	2019	PI3K/AKT signaling pathway was suppressed with downregulation of VEGF expression in osteoblasts after ACY-1215 treatment.	ricolinostat	102-110	AKT serine/threonine kinase 1	Homo sapiens	5-8
31548177-5	2019	PI3K/AKT signaling pathway was suppressed with downregulation of VEGF expression in osteoblasts after ACY-1215 treatment.	ricolinostat	102-110	vascular endothelial growth factor A	Homo sapiens	65-69
31548177-7	2019	Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1beta-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts.	ricolinostat	128-136	matrix metallopeptidase 9	Homo sapiens	58-62
31548177-7	2019	Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1beta-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts.	ricolinostat	128-136	matrix metallopeptidase 13	Homo sapiens	67-72
31548177-7	2019	Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1beta-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts.	ricolinostat	128-136	interleukin 1 beta	Homo sapiens	76-84
31548177-8	2019	These data of immunohistochemistry and micro-CT from OA model mice also demonstrated the weak staining of MMPs in cartilage and prevention of aberrant subchondral bone formation after ACY-1215 injection.	ricolinostat	184-192	matrix metallopeptidase 9	Homo sapiens	106-110